Sign up for a new account.
And get access to
The latest T1D content
Research that matters
Our daily questions
Sign up by entering your info below.
Sign in to your account with
Reset Your Password
We will email you instructions to reset your
D. Desalvo1, O. Ebekozien2, E. Ospelt2, M. Kamboj3, E. Cobry4, S. Polsky4, R. Izquierdo5, R. Mcdonough6, S. Ogburn7, C. Demeterco‐Berggren8, L. Jacobson9, R. Sonabend1, N. Noor2
Background and Aims: Evidence from clinical trials have demonstrated the glycemic benefits of hybrid closed‐loop insulin delivery systems (HCLS) in children and adults. The primary objective of this study was to provide real‐world data on glycemic outcomes and population characteristics in those using HCLS compared to other treatment modalities.
Methods: Electronic health record data (2019‐2021) from the T1D Exchange Quality Improvement (T1DX‐QI) Collaborative were analyzed for 15,091 people with T1D. Patients with data on insulin delivery mode [HCLS, sensor-augmented pump therapy (SAP), pump only, or multiple daily injections (MDI)], A1c at their most recent clinic visit, and other demographic covariates were included in this analysis. Individuals were classified across insulin delivery groups based on information documented by a healthcare provider at their most recent clinic visit.
Full study abstract listed under number OP049 / #141 at this link
This site uses Akismet to reduce spam. Learn how your comment data is processed.
Hybrid Closed Loop Systems and Glycemic Outcomes in Children and Adults with Type 1 Diabetes: Real World Evidence From U.S. Based Multi-Center Collaborative
You must be logged in to post a comment.